Calcilytix Therapeutics, Inc. clinical trials

A subsidiary of BridgeBio

The registry lists 5 studies whose lead sponsor is Calcilytix Therapeutics, Inc.. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 16, 2026.

Status

Recruiting: 2
Active, not recruiting: 2
Completed: 1

Phase

Phase 3: 3
Phase 2: 2

Where

United States: 5
United Kingdom: 3
Canada: 3
Japan: 2
Italy: 2
Australia: 2

Registry sponsor names on this page

Calcilytix Therapeutics, Inc., a BridgeBio company5 studies

Something wrong with this grouping? Tell us on the BridgeBio page.

Studies

Recruiting first, then most recently updated. Showing 5 of 5. All BridgeBio studies →

Efficacy, Safety, and Tolerability of Encaleret in Participants With Chronic HypoparathyroidismRecruitingNCT07805356Phase 3
Sponsor listed in the registry: Calcilytix Therapeutics, Inc., a BridgeBio company
Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)RecruitingNCT07080385Phase 2/3
Sponsor listed in the registry: Calcilytix Therapeutics, Inc., a BridgeBio company
Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1Active, not recruitingNCT05680818Phase 3
Sponsor listed in the registry: Calcilytix Therapeutics, Inc., a BridgeBio company
ADH1 and ADH2 Disease Monitoring Study (DMS)Active, not recruitingNCT05227287
Sponsor listed in the registry: Calcilytix Therapeutics, Inc., a BridgeBio company
Safety, Tolerability, and Efficacy of Encaleret in Participants With Autosomal Dominant Hypocalcemia (ADH) Type 1CompletedNCT04581629Phase 2
Sponsor listed in the registry: Calcilytix Therapeutics, Inc., a BridgeBio company